NOVO NORDISK A/S (NYSE: NVO)

NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

最近更新时间: 6天之前, 4:08PM

59.43

0.10 (0.17%)

加入群组

前收盘价格	59.33
收盘价格	59.27
成交量	11,639,652
平均成交量 (3个月)	20,722,470
市值	264,075,984,896

市盈率 (P/E TTM)	15.81
预期市盈率 (P/E Forward)	13.99
价格/销量 (P/S)	4.58
股市价格/股市净资产 (P/B)	7.29

52周波幅	43.08 (-27%) — 93.80 (57%)
利润日期	4 Feb 2026
股息率 (DY TTM)	1.85%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看涨	混合的
	Drug Manufacturers - General (全球的)	看涨	混合的
股票	Novo Nordisk A/S	看涨	看跌

AIStockmoo 评分

0.0

分析师共识	-1.5
内部交易活动	NA
价格波动	2.0
技术平均移动指标	-2.5
技术振荡指标	2.0
平均	0.00

相关股票

股票	市值	DY	P/E（TTM）	P/B
NVO	264 B	1.85%	15.81	7.29
NVS	272 B	3.27%	19.43	6.37
LLY	936 B	0.14%	51.28	39.98
JNJ	573 B	0.52%	21.58	7.08
ABBV	399 B	0.73%	169.65	50.46
MRK	270 B	0.75%	14.29	5.55

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Core
内部持股比例	0.01%
机构持股比例	9.85%

所有权

姓名	日期	持有股份
Folketrygdfondet	30 Sep 2025	10,211,913
Fayez Sarofim & Co	30 Sep 2025	7,353,587
Everett Harris & Co /Ca/	30 Sep 2025	6,393,780

52周波幅	43.08 (-27%) — 93.80 (57%)
目标价格波幅	46.00 (-22%) — 73.50 (23%)
高	73.50 (CICC, 23.68%)	购买
中	54.00 (-9.14%)
低	46.00 (BMO Capital, -22.60%)	保留
平均值	57.83 (-2.69%)
总计	2 购买, 1 保留
平均价格@调整类型	51.74

公司	日期	目标价格	调整类型	价格@调整类型
CICC	09 Jan 2026	73.50 (23.67%)	购买	58.81
Goldman Sachs	28 Nov 2025	54.00 (-9.14%)	购买	49.35
BMO Capital	25 Nov 2025	46.00 (-22.60%)	保留	47.06

该时间范围内无数据。

日期	类型	细节
05 Feb 2026	CNBC	The White House is launching direct-to-consumer drug site Trump Rx. Here's what to know
04 Feb 2026	公告	Novo Nordisk initiates 2026 share repurchase programme
04 Feb 2026	公告	Novo Nordisk has published its annual report for 2025
04 Feb 2026	CNBC	Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
04 Feb 2026	CNBC	Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
03 Feb 2026	公告	Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
03 Feb 2026	公告	Novo Nordisk releases 2026 sales and operating profit outlook
03 Feb 2026	CNBC	Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
02 Feb 2026	公告	Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
31 Jan 2026	公告	New employee representative on the Board of Directors of Novo Nordisk A/S
30 Jan 2026	CNBC	Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
30 Jan 2026	CNBC	Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
23 Jan 2026	CNBC	What obesity drugmakers see next in the market: More pills, easier access and drug combinations
20 Jan 2026	公告	Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
20 Jan 2026	CNBC	Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
16 Jan 2026	CNBC	Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026	CNBC	2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026	CNBC	Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
05 Jan 2026	CNBC	First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
05 Jan 2026	公告	Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
31 Dec 2025	公告	Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
22 Dec 2025	CNBC	FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
22 Dec 2025	公告	Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
19 Dec 2025	CNBC	Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple
12 Dec 2025	公告	Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
11 Dec 2025	CNBC	Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
09 Dec 2025	公告	Novo Nordisk has completed its acquisition of Akero Therapeutics
01 Dec 2025	CNBC	Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
25 Nov 2025	公告	Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
24 Nov 2025	CNBC	Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
24 Nov 2025	公告	Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
17 Nov 2025	CNBC	Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
17 Nov 2025	公告	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
14 Nov 2025	公告	Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
13 Nov 2025	公告	Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
11 Nov 2025	公告	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2025	公告	Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
07 Nov 2025	CNBC	Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025	CNBC	Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025	CNBC	Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
06 Nov 2025	CNBC	Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025	公告	Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
06 Nov 2025	公告	Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
05 Nov 2025	公告	Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
05 Nov 2025	公告	Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
显示更多

股息率 (DY TTM)	1.85%
5年平均股息收益率	2.17%
股息支付比率	47.09%

除息日	公告日期	支付日期	详情
31 Mar 2025	05 Feb 2025	08 Apr 2025	1.099206 现金
16 Aug 2024	06 Aug 2024	26 Aug 2024	0.5126402 现金
22 Mar 2024	31 Jan 2024	02 Apr 2024	0.92985 现金
18 Aug 2023	10 Aug 2023	29 Aug 2023	0.8835613 现金
24 Mar 2023	02 Feb 2023	04 Apr 2023	1.1887415 现金
12 Aug 2022	04 Aug 2022	23 Aug 2022	0.5835507 现金
25 Mar 2022	02 Mar 2022	05 Apr 2022	1.022423 现金
16 Aug 2021	-	25 Aug 2021	0.5502889 现金
26 Mar 2021	-	07 Apr 2021	0.922122 现金
14 Aug 2020	06 Aug 2020	25 Aug 2020	0.5177774 现金
27 Mar 2020	06 Feb 2020	07 Apr 2020	0.7826048 现金
16 Aug 2019	10 Aug 2019	27 Aug 2019	0.449438 现金
22 Mar 2019	05 Feb 2019	02 Apr 2019	0.777006 现金
17 Aug 2018	09 Aug 2018	28 Aug 2018	0.462327 现金
23 Mar 2018	24 Mar 2018	03 Apr 2018	0.805982 现金
17 Aug 2017	-	29 Aug 2017	0.33589 现金
23 Mar 2017	-	04 Apr 2017	0.479369 现金
11 Aug 2016	-	23 Aug 2016	0.331026 现金
18 Mar 2016	-	30 Mar 2016	0.69943 现金
19 Mar 2015	-	31 Mar 2015	0.532885 现金
21 Mar 2014	-	02 Apr 2014	0.606122 现金
21 Mar 2013	-	02 Apr 2013	2.264307 现金
22 Mar 2012	-	03 Apr 2012	1.831902 现金
24 Mar 2011	-	05 Apr 2011	1.357901 现金
25 Mar 2010	-	07 Apr 2010	0.978615 现金
19 Mar 2009	-	31 Mar 2009	0.781532 现金
13 Mar 2008	-	25 Mar 2008	0.678462 现金
08 Mar 2007	-	20 Mar 2007	0.891779 现金
09 Mar 2006	-	21 Mar 2006	0.691753 现金
10 Mar 2005	-	22 Mar 2005	0.61725 现金
17 Mar 2004	-	29 Mar 2004	0.52096 现金
26 Mar 2003	-	07 Apr 2003	0.37647 现金
13 Mar 2002	-	25 Mar 2002	0.2848 现金
21 Mar 2001	-	02 Apr 2001	0.5681 现金
24 Mar 2000	-	06 Apr 2000	0.4672 现金
25 Mar 1999	-	06 Apr 1999	0.4182 现金
27 Mar 1998	-	08 Apr 1998	0.3051 现金
25 Apr 1997	-	07 May 1997	0.239 现金
01 May 1996	-	14 May 1996	0.1806 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.10	1	2.16
2024	1.44	2	1.68
2023	2.07	2	2.00
2022	1.61	2	2.37
2021	1.47	2	2.63
2020	1.30	2	3.72
2019	1.23	2	4.24
2018	1.27	2	5.51
2017	0.815	2	3.04
2016	1.03	2	5.75
2015	0.533	1	1.84
2014	0.606	1	2.86
2013	2.26	1	12.26
2012	1.83	1	11.22
2011	1.36	1	11.78
2010	0.979	1	8.69
2009	0.782	1	12.24
2008	0.678	1	13.20
2007	0.892	1	13.75
2006	0.692	1	16.54
2005	0.617	1	21.94
2004	0.521	1	19.20
2003	0.376	1	18.38
2002	0.285	1	19.71
2001	0.568	1	28.33
2000	0.467	1	26.40
1999	0.418	1	32.36
1998	0.305	1	22.94
1997	0.239	1	16.57
1996	0.181	1	19.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2026	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	34.51%
营业利益率 (TTM)	49.68%
稀释每股收益 (EPS TTM)	3.67
季度收入增长率 (YOY)	19.50%
季度盈利增长率 (YOY)	14.30%

总债务/股东权益 (D/E MRQ)	85.70%
流动比率 (MRQ)	0.740
营业现金流 (OCF TTM)	131.24 B
杠杆自由现金流 (LFCF TTM)	77.73 B

资产报酬率 (ROA TTM)	23.29%
股东权益报酬率 (ROE TTM)	88.12%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)